CTC in women with advanced oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive phenotype after multiple courses of therapy (217, 218). This evidence concerns the gene ERBB2 and breast carcinoma.